Published in Nat Rev Urol on February 12, 2013
Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98
Application of radiation technology in vaccines development. Clin Exp Vaccine Res (2015) 0.78
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
Diaminosulfide based polymer microparticles as cancer vaccine delivery systems. J Control Release (2015) 0.77
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. J Immunol Res (2016) 0.75
The value of EGFRvIII as the target for glioma vaccines. Am Soc Clin Oncol Educ Book (2014) 0.75
Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Control Release (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Toll-like receptors in the induction of the innate immune response. Nature (2000) 12.23
Dendritic cells: specialized and regulated antigen processing machines. Cell (2001) 10.44
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem (1978) 5.43
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science (2008) 5.04
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 3.53
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol (2009) 3.51
Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol (2006) 3.44
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med (2007) 2.98
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol (1999) 2.65
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res (1993) 2.54
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 2.33
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Vaccinia virus immune evasion. Immunol Rev (1997) 2.03
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate (2004) 1.50
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther (2005) 1.29
Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog (2007) 1.28
Cellular vaccine approaches. Cancer J (2010) 1.27
Use of viral vectors for the development of vaccines. Expert Rev Vaccines (2007) 1.25
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3. J Virol (2008) 1.16
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res (2002) 1.14
Immunization with DNA through the skin. Methods (2003) 1.13
Gene vaccines. Ann Intern Med (2003) 1.13
Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol (2006) 1.12
Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem (2011) 1.12
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol (2007) 1.06
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06
Prostate tumor biology and cell kinetics--theory. Urology (1981) 1.05
Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol (2007) 1.05
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer (2006) 1.02
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol (2001) 1.00
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther (2006) 0.98
Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer (2001) 0.97
Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate (2005) 0.97
Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol (2009) 0.96
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine (2006) 0.93
Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res (2011) 0.93
Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther (1996) 0.92
Smallpox: an ancient disease enters the modern era of virogenomics. Proc Natl Acad Sci U S A (2004) 0.89
Prostate cancer vaccines in clinical trials. Expert Rev Vaccines (2012) 0.89
Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother (2011) 0.88
Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation. Virology (2006) 0.88
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys (2004) 0.88
Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother (2009) 0.86
NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J Immunol (2010) 0.84
Effect of granulocyte-macrophage colony-stimulating factor on the generation of epidermal Langerhans cells. J Interferon Cytokine Res (2000) 0.83
Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PLoS One (2012) 0.82
Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Hum Gene Ther (2006) 0.80
An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther (2011) 0.78
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol (2011) 0.78
Comparative analysis of CD80 and CD86 on human Langerhans cells: expression and function. Arch Dermatol Res (1998) 0.76
Cyclophosphamide, DCs, and Tregs. Blood (2010) 0.76
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun (2010) 1.61
Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol (2005) 1.61
Glucose as a prognostic factor in ovarian carcinoma. Cancer (2009) 1.59
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol (2008) 1.56
Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2003) 1.48
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res (2008) 1.46
Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release (2008) 1.42
Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol (2012) 1.40
Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun (2010) 1.39
Optimization of yield in magnetic cell separations using nickel nanowires of different lengths. Biotechnol Prog (2005) 1.37
Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate (2002) 1.32
Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev (2009) 1.28
Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway. Immunity (2006) 1.26
Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother (2007) 1.24
Nanoparticle delivery systems in cancer vaccines. Pharm Res (2010) 1.20
Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun (2008) 1.13
Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. J Pharm Sci (2008) 1.11
Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial biogenesis and function. Mol Cell Biol (2011) 1.10
The enhancement of bone regeneration by gene activated matrix encoding for platelet derived growth factor. Biomaterials (2013) 1.10
Biodegradable particles as vaccine delivery systems: size matters. AAPS J (2012) 1.09
Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer (2007) 1.06
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun (2012) 1.03
Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J Microencapsul (2008) 1.02
Fabrication, characterization and in vitro evaluation of poly(D,L-lactide-co-glycolide) microparticles loaded with polyamidoamine-plasmid DNA dendriplexes for applications in nonviral gene delivery. J Pharm Sci (2010) 1.02
Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. Int J Pharm (2011) 1.01
A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci (2007) 1.01
Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer (2010) 1.01
Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem (2004) 1.00
Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98
Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun (2012) 0.97
Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem (2007) 0.97
Effect of crystal size and surface functionalization on the cytotoxicity of silicalite-1 nanoparticles. Chem Res Toxicol (2009) 0.96
Pulsatile release of biomolecules from polydimethylsiloxane (PDMS) chips with hydrolytically degradable seals. J Control Release (2008) 0.95
Development of the neonatal B and T cell repertoire in swine: implications for comparative and veterinary immunology. Vet Res (2006) 0.94
Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res (2014) 0.93
Modulation of T cell activation by stomatin-like protein 2. J Immunol (2008) 0.91
Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J (2014) 0.91
Optimized dextran-polyethylenimine conjugates are efficient non-viral vectors with reduced cytotoxicity when used in serum containing environments. Int J Pharm (2011) 0.90
Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother (2008) 0.90
Rational design, fabrication, characterization and in vitro testing of biodegradable microparticles that generate targeted and sustained transgene expression in HepG2 liver cells. J Drug Target (2010) 0.87
Heterogeneous Expression of Invasive and Metastatic Properties in a Prostate Tumor Model. Pathol Oncol Res (1997) 0.87
Antibody repertoire development in fetal and neonatal piglets: XIX. Undiversified B cells with hydrophobic HCDR3s preferentially proliferate in the porcine reproductive and respiratory syndrome. J Immunol (2007) 0.86
The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS One (2013) 0.85
Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A (2012) 0.84
Applying biodegradable particles to enhance cancer vaccine efficacy. Immunol Res (2014) 0.84
Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles. Acta Biomater (2012) 0.84
CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Deliv Rev (2009) 0.84
Chitosan coating of copper nanoparticles reduces in vitro toxicity and increases inflammation in the lung. Nanotechnology (2013) 0.84
Rapid localized cell trapping on biodegradable polymers using cell surface derivatization and microfluidic networking. Biomaterials (2005) 0.82
Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J (2014) 0.82
A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J (2014) 0.81
Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun (2007) 0.80
Intracellular release of 17-β estradiol from cationic polyamidoamine dendrimer surface-modified poly (lactic-co-glycolic acid) microparticles improves osteogenic differentiation of human mesenchymal stromal cells. Tissue Eng Part C Methods (2010) 0.80
Spatial control over cell attachment by partial solvent entrapment of poly lysine in microfluidic channels. Int J Nanomedicine (2006) 0.79
Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines (2014) 0.79
Efficacy of polymeric encapsulated C5a peptidase-based group B streptococcus vaccines in a murine model. Am J Obstet Gynecol (2011) 0.79
New class of biodegradable polymers formed from reactions of an inorganic functional group. Macromolecules (2012) 0.79
Manipulation of Cell Physiology Enables Gene Silencing in Well-differentiated Airway Epithelia. Mol Ther Nucleic Acids (2012) 0.78
The absence of CpG in plasmid DNA-chitosan polyplexes enhances transfection efficiencies and reduces inflammatory responses in murine lungs. Mol Pharm (2014) 0.78
Biotinylated biodegradable nanotemplated hydrogel networks for cell interactive applications. Biomacromolecules (2008) 0.78
Silicalite nanoparticles that promote transgene expression. Nanotechnology (2008) 0.78
Microparticles prepared from sulfenamide-based polymers. J Microencapsul (2013) 0.78
Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations. Biomaterials (2013) 0.78
Glucocorticoid receptor antagonist and siRNA prevent senescence of human bone marrow mesenchymal stromal cells in vitro. Cell Tissue Res (2013) 0.77
Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. Mol Pharm (2011) 0.77
A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy (2014) 0.77
Mitochondria-targeting particles. Nanomedicine (Lond) (2014) 0.77
Synthesis of the first poly(diaminosulfide)s and an investigation of their applications as drug delivery vehicles. Macromolecules (2012) 0.76
Multifunctional nanorods for biomedical applications. Pharm Res (2007) 0.76
Recent progress in non-viral nucleic acids delivery. Int J Pharm (2011) 0.76
Production of antigen-loaded biodegradable nanoparticles and uptake by dendritic cells. Methods Mol Biol (2014) 0.76
Immunostimulatory sutures that treat local disease recurrence following primary tumor resection. Biomed Mater (2011) 0.76
Gene-Activated Titanium Surfaces Promote In Vitro Osteogenesis. Int J Oral Maxillofac Implants (2016) 0.76
A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects. Curr Pharm Biotechnol (2015) 0.75
Correction: MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. PLoS One (2016) 0.75
Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells. Pharm Dev Technol (2012) 0.75
Effect of combined locally delivered growth factors and systemic sildenafil citrate on microrecanalization in biodegradable conduit for vas deferens reconstruction. Urology (2012) 0.75
Recent progress on the development of gene-activated scaffolds encoding PDGF for enhanced bone regeneration. Regen Med (2014) 0.75